OXFORD BIODYNAMICS LS-01

F:LMQ Germany Diagnostics & Research
Market Cap
$2.20 Million
€2.15 Million EUR
Market Cap Rank
#34939 Global
#4073 in Germany
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.02
All Time High
€1.18
About

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more

OXFORD BIODYNAMICS LS-01 (LMQ) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, OXFORD BIODYNAMICS LS-01 (LMQ) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

OXFORD BIODYNAMICS LS-01 - Net Assets Trend (None–None)

This chart illustrates how OXFORD BIODYNAMICS LS-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for OXFORD BIODYNAMICS LS-01 (None–None)

The table below shows the annual net assets of OXFORD BIODYNAMICS LS-01 from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to OXFORD BIODYNAMICS LS-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

OXFORD BIODYNAMICS LS-01 Competitors by Market Cap

The table below lists competitors of OXFORD BIODYNAMICS LS-01 ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OXFORD BIODYNAMICS LS-01's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares OXFORD BIODYNAMICS LS-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently OXFORD BIODYNAMICS LS-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares OXFORD BIODYNAMICS LS-01's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $10,792,710,184
  • Average return on equity (ROE) among peers: -33.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
OXFORD BIODYNAMICS LS-01 (LMQ) €- N/A N/A $1.57 Million
Spermosens AB (publ) (9R5) $23.64 Million -27.17% 0.09x $517.28K
BML Inc (BMZ) $81.13 Billion 8.19% 0.43x $462.01 Million
Genomic Vision Société Anonyme (G09) $3.07 Million -162.85% 1.21x $711.54K
ICON Public Limited Company (IJF) $1.85 Billion 17.96% 0.86x $6.43 Billion
Adicon Holdings Limited (K0U) $1.77 Billion 2.65% 1.64x $138.53 Million
WuXi XDC Cayman Inc. (L74) $1.48 Billion 10.52% 0.69x $2.11 Billion
NanoRepro AG (NN6) $57.61 Million 51.59% 0.37x $16.84 Million
PERRIGO (PGO) $24.67 Million -167.93% 0.99x $6.37K